keyword
MENU ▼
Read by QxMD icon Read
search

FIB-4

keyword
https://www.readbyqxmd.com/read/27920479/ceruloplasmin-a-reliable-marker-of-fibrosis-in-chronic-hepatitis-b-virus-patients-with-normal-or-minimally-raised-alanine-aminotransferase
#1
Da-Wu Zeng, Jing Dong, Jia-Ji Jiang, Yue-Yong Zhu, Yu-Rui Liu
AIM: To develop a non-invasive model to evaluate significant fibrosis and cirrhosis by investigating the association between serum ceruloplasmin (CP) levels and liver fibrosis in chronic hepatitis B (CHB) patients with normal or minimally raised alanine aminotransferase (ALT). METHODS: Serum samples and liver biopsy were obtained from 193 CHB patients with minimally raised or normal ALT who were randomly divided into a training group (n = 97) and a validation group (n = 96)...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27897323/prognostic-durability-of-liver-fibrosis-tests-and-improvement-in-predictive-performance-for-mortality-by-combining-tests
#2
Sandrine Bertrais, Jérôme Boursier, Alexandra Ducancelle, Frédéric Oberti, Isabelle Fouchard-Hubert, Valérie Moal, Paul Calès
BACKGROUND AND AIM: There is currently no recommended time interval between non-invasive fibrosis measurements for monitoring chronic liver diseases. We determined how long a single liver fibrosis evaluation may accurately predict mortality, and assessed whether combining tests improves prognostic performance. METHODS: We included 1559 patients with chronic liver disease and available baseline liver stiffness measurement (LSM) by Fibroscan, APRI, FIB-4, Hepascore, and FibroMeter(V2G) ...
November 29, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27875352/does-incorporating-change-in-apri-or-fib-4-indices-over-time-improve-the-accuracy-of-a-single-index-for-identifying-liver-fibrosis-in-persons-with-chronic-hepatitis-c-virus-infection
#3
Prabhu P Gounder, Celia Haering, Dana J T Bruden, Lisa Townshend-Bulson, Brenna C Simons, Philip R Spradling, Brian J McMahon
BACKGROUND: The aspartate aminotransferase-to-platelet ratio index (APRI) and a fibrosis index calculated using platelets (FIB-4) have been proposed as noninvasive markers of liver fibrosis. GOALS: To determine APRI/FIB-4 accuracy for predicting histologic liver fibrosis and evaluate whether incorporating change in index improves test accuracy in hepatitis C virus (HCV)-infected Alaska Native persons. STUDY: Using liver histology as the gold standard, we determined the test characteristics of APRI to predict Metavir ≥F2 fibrosis and FIB-4 to predict Metavir ≥F3 fibrosis...
November 21, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27859587/gamma-glutamyl-transpeptidase-to-platelet-ratio-is-an-independent-predictor-of-hepatitis-b-virus-related-liver-cancer
#4
Yong Eun Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sojung Han, Mi Young Jeon, Ja Yoon Heo, Kijun Song, Seung Up Kim
BACKGROUND AND AIMS: Gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can evaluate the degree of liver fibrosis. We investigated whether GPR can predict the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. METHODS: We retrospectively evaluated 1,109 CHB patients that were enrolled between 2006 and 2012, and all patients had available data for the assessment of GPR at enrollment. Three risk groups were defined according to tertile stratification: GPR < 0...
November 16, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27859583/external-validation-of-the-nonalcoholic-fatty-liver-disease-fibrosis-score-for-assessing-advanced-fibrosis-in-korean-patients
#5
Dae Won Jun, Sang Gyune Kim, Sang Hoon Park, So-Young Jin, Ji Sung Lee, Jin-Woo Lee, Moon Young Kim, Dae Hee Choi, Yong Kyun Cho, Jong Eun Yeon, Joo Hyun Sohn
BACKGROUND: The degree of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) is a critical predictive factor for patient prognosis. This study was intended to perform external validation of the various fibrosis prediction models for assessing advanced fibrosis in Korean NAFLD patients. METHODS: A retrospective study of 412 patients with NAFLD confirmed by liver biopsy in hospitals affiliated with the Koran NAFLD study group was conducted and the predictive ability of existing liver fibrosis prediction models including NAFLD fibrosis score (NFS), BARD, and FIB-4 were compared...
November 11, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27822295/infection-with-hepatitis-viruses-fib-4-index-and-risk-of-hepatocellular-carcinoma-in-southern-italy-a-population-based-cohort-study
#6
Mario Fusco, Pierluca Piselli, Saverio Virdone, Pietro Di Cicco, Paola Scognamiglio, Paolo De Paoli, Valerio Ciullo, Diana Verdirosi, Michele D'Orazio, Luigino Dal Maso, Enrico Girardi, Silvia Franceschi, Diego Serraino
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) and its association with hepatitis C (HCV) and hepatitis B virus (HBV) infections, FIB-4 index and liver enzymes was assessed in an area of the province of Naples covered by a population-based cancer registry. METHODS: We conducted a cohort investigation on 4492 individuals previously enrolled in a population-based seroprevalent survey on HCV and HBV infections. The diagnosis of HCC was assessed through a record linkage with the cancer registry...
2016: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/27813162/do-directly-acting-antiviral-agents-for-hcv-increase-the-risk-of-hepatic-decompensation-and-decline-in-renal-function-results-from-erchives
#7
A A Butt, Y Ren, K Marks, O S Shaikh, K E Sherman
BACKGROUND: Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre-treatment cirrhosis, but this risk is not well defined. AIM: To determine the incidence of hepatic decompensation, liver transplantation, death and worsening renal function in patients treated with a Paritaprevir/ritonavir, Ombitasvir, Dasabuvir (PrOD), sofosbuvir/simeprevir or sofosbuvir/ledipasvir regimen. METHODS: We followed ERCHIVES participants treated with the above regimens for up to 12 weeks post-treatment...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27813124/noninvasive-markers-for-staging-fibrosis-in-chronic-delta-hepatitis
#8
V Takyar, P Surana, D E Kleiner, K Wilkins, J H Hoofnagle, T J Liang, T Heller, C Koh
BACKGROUND: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV). AIM: To evaluate the utility of serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, aspartate aminotransferase ratio (AAR), age-platelet index (API), AST-to-platelet-ratio-index (APRI) and Hui score] in HDV infection. METHODS: Clinical and histologic laboratory data from HBV, HCV and HDV patients were evaluated and serum fibrosis markers were calculated...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27812720/logiq-e9-shear-wave-elastrography-for-detection-of-liver-fibrosis-in-patients-with-chronic-hepatitis-c-virus
#9
Gary A Abrams, Hira Jamal, William T Deeter, Nirav Patil
OBJECTIVES: Shear wave elastography (SWE) is an emerging technology that assesses hepatic fibrosis. The aim of our study was to determine the diagnostic accuracy of General Electric (GE) Healthcare's LOGIQ E9 SWE in patients with chronic hepatitis C virus using liver biopsy as the reference standard. METHODS: The liver stiffness of 43 subjects with hepatitis C virus was assessed using LOGIQ E9 SWE immediately before they underwent liver biopsy. The Fibrosis-4 Index (FIB-4) and Aspartate Aminotransferase-to-Platelet Index (APRI) were calculated, and the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were determined...
November 2016: Southern Medical Journal
https://www.readbyqxmd.com/read/27788722/-value-of-non-invasive-models-of-liver-fibrosis-in-judgment-of-treatment-timing-in-chronic-hepatitis-b-patients-with-alt-2%C3%A3-upper-limit-of-normal
#10
Q Q Zhou, Y B Hu, K Zhou, W W Zhang, M H Li, P Dong, J G Di, L Hong, Q W Du, Y Xie, Q F Sun
Objective: To investigate the value of non-invasive liver fibrosis models, FIB-4, S index, aspartate aminotransferase to platelet ratio index(APRI), globulin-platelet(GP)model, aspartate aminotransferase/platelet/gamma-glutamyl transpeptidase/alpha-fetoprotein(APGA), and platelet/age/phosphatase/alpha-fetoprotein/aspartate aminotransferase(PAPAS), in the diagnosis of marked liver fibrosis in chronic hepatitis B(CHB)patients with ALT < 2×upper limit of normal(ULN), as well as treatment timing for this population...
September 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/27755232/fib-4-and-imaging-for-measuring-fibrosis-in-hepatitis-c-virus
#11
Barbara J Turner, Yuanyuan Liang, Amit Singal
OBJECTIVES: Noninvasive measures are widely used to assess fibrosis and may be used to prioritize hepatitis C virus (HCV) treatment. We examined risks for likely fibrosis in patients with chronic HCV infection using fibrosis-4 (FIB-4) and imaging. PATIENTS AND METHODS: A HCV screening program diagnosed chronic HCV in patients born from 1945 to 1965 admitted in a safety net hospital. Likely fibrosis was based on FIB-4 (≥1.45) alone or combined with imaging interpreted as fibrosis or cirrhosis...
October 17, 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27755117/interferon-based-hepatitis-c-therapy-in-a-safety-net-hospital-access-efficacy-and-safety
#12
Eric M Nordstrom, Angela Keniston, Fafa Baouchi, Alvaro Martinez-Camacho
AIMS: This study assesses the efficacy, accessibility, and safety of hepatitis C virus (HCV) treatment in a safety net hospital population. METHODS: Patients at Denver Health receiving pegylated interferon for HCV infection between 2008 and 2012 were included in this retrospective study. Sociodemographic, biochemical, and virologic data were collected on each patient. The primary outcomes were the rate of sustained virologic response and early treatment discontinuation, with reason for discontinuation documented...
January 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27753194/performance-of-transient-elastography-in-japanese-patients-with-non-alcoholic-fatty-liver-disease
#13
Kojiro Seki, Toshihide Shima, Hirohisa Oya, Yasuhide Mitsumoto, Masayuki Mizuno, Takeshi Okanoue
AIM: Transient elastography (TE) is a noninvasive method for predicting liver fibrosis. However, there is limited data regarding the performance of TE in Japanese patients with nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the association between liver stiffness measurement (LSM) by TE and liver fibrosis stage, and define a cut-off value for predicting liver fibrosis. METHODS: A total of 171 Japanese patients with biopsy-proven NAFLD underwent LSM using TE with FibroScan®...
October 18, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27740519/%C3%A2-chemerin-retinol-binding-protein-4-cytokeratin-18-and-transgelin-2-presence-in-sera-of-patients-with-non-alcoholic-liver-fatty-disease
#14
Agnieszka Zwolak, Agnieszka Szuster-Ciesielska, Jadwiga Daniluk, Justyna Semeniuk, Martyna Kandefer-Szerszen
:  Background. Chemerin and retinol binding protein-4 (RBP-4) are adipokines which may play a role in the progression of NAFLD. It has been also suggested that cytokeratin-18 (CK-18) could be a marker of hepatocyte caspase-directed death while transgelin-2 production could reflect stage of liver fibrosis. The aim of this study was to evaluate the level of the above adipokines in sera of patients with NAFLD and determine the relation between the level of transgelin-2 and fibrosis-4 index (FIB-4)...
November 2016: Annals of Hepatology
https://www.readbyqxmd.com/read/27731343/microrna-based-diagnostic-tools-for-advanced-fibrosis-and-cirrhosis-in-patients-with-chronic-hepatitis-b-and-c
#15
Kevin Appourchaux, Safi Dokmak, Matthieu Resche-Rigon, Xavier Treton, Martine Lapalus, Charles-Henry Gattolliat, Emmanuelle Porchet, Michelle Martinot-Peignoux, Nathalie Boyer, Michel Vidaud, Pierre Bedossa, Patrick Marcellin, Ivan Bièche, Emilie Estrabaud, Tarik Asselah
Staging fibrosis is crucial for the prognosis and to determine the rapid need of treatment in patients with chronic hepatitis B (CHB) and C (CHC). The expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4). In CHB patients, the model (serum miR-122, serum miR-222, platelet count and alkaline phosphatase) was more accurate than APRI and FIB-4 to discriminate in between mild and moderate fibrosis (F1-F2) and F3-F4 (AUC of CHB model: 0...
October 12, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27725647/age-as-a-confounding-factor-for-the-accurate-non-invasive-diagnosis-of-advanced-nafld-fibrosis
#16
Stuart McPherson, Tim Hardy, Jean-Francois Dufour, Salvatore Petta, Manuel Romero-Gomez, Mike Allison, Claudia P Oliveira, Sven Francque, Luc Van Gaal, Jörn M Schattenberg, Dina Tiniakos, Alastair Burt, Elisabetta Bugianesi, Vlad Ratziu, Christopher P Day, Quentin M Anstee
OBJECTIVES: Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS: Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (FIB-4), and NAFLD fibrosis score (NFS) for advanced fibrosis (stage F3-F4) for each group was assessed using liver biopsy as the standard...
October 11, 2016: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27712017/real-life-egyptian-experience-of-efficacy-and-safety-of-simeprevir-sofosbuvir-therapy-in-6211-chronic-hcv-genotype-iv-infected-patients
#17
Rasha Eletreby, Wafaa Elakel, Mohamed Said, Mohamed Elkassas, Sameh Seif, Tamer Elbaz, Maissa El Raziky, Siham Abdel Rehim, Samy Zaky, Rabab Fouad, Hadeel Gamal, Mahmoud Abdo, Mohamed Korany, Ayman Yosry, Magdy El Serafy, Manal Hamdy El-Sayed, Yehia ElShazly, Imam Waked, Wahid Doss, Gamal Esmat
BACKGROUND & AIM: Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of sustained virological response (SVR), even in difficult-to-treat patients. This study explores real life experience concerning efficacy, safety and possible predictors of response for the first cohort of Egyptian patients with chronic HCV genotype IV treated with Sofosbuvir / Simprevir combination therapy...
October 6, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27704012/serum-fibrosis-markers-for-the-diagnosis-of-liver-disease-among-people-with-chronic-hepatitis-c-in-chennai-india
#18
Javier A Cepeda, Sunil S Solomon, Aylur K Srikrishnan, Paneerselvam Nandagopal, Pachamuthu Balakrishnan, Muniratnam S Kumar, David L Thomas, Mark S Sulkowski, Shruti H Mehta
Background.  Access to hepatitis C virus (HCV) treatment is limited in low- and middle-income countries (LMICs). Noninvasive biomarkers, such as fibrosis 4 (FIB-4) and aminotransferase to platelet ratio index (APRI), are low-cost alternatives to staging liver disease and identifying treatment need in people with chronic HCV infection, but their accuracy has not been evaluated in LMICs. Methods.  We tested the accuracy of FIB-4 and APRI at validated cutoffs (FIB-4 <1.45, >3.25; APRI <0.5, >1...
September 2016: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/27685251/metabolic-and-hepatic-effects-of-bloodletting-in-dysmetabolic-iron-overload-syndrome-a-randomized-controlled-study-in-274-patients
#19
Fabrice Lainé, Marc Ruivard, Véronique Loustaud-Ratti, Fabrice Bonnet, Paul Calès, Edouard Bardou-Jacquet, Sylvie Sacher-Huvelin, Xavier Causse, Christine Beusnel, Alain Renault, Eric Bellissant, Yves Deugnier
: Dysmetabolic iron overload syndrome (DIOS) is a common cause of hyperferritinemia, accounting for a mild increase of iron stores in insulin-resistant subjects. Iron removal could improve insulin sensitivity. We performed a prospective, randomized, controlled trial (NCT01015525) in nondiabetic DIOS patients with hepatic iron >50 μmol/g at magnetic resonance imaging to compare the metabolic and hepatic outcomes of 1-year maintenance of serum ferritin levels <50 μg/L by bloodletting associated with lifestyle and diet advice (LFDA) to those of LFDA only...
September 29, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27678216/daa-treatment-of-chronic-hepatitis-c-results-in-rapid-regression-of-transient-elastography-and-fibrosis-markers-fib-4-and-apri
#20
Jacqueline A Bachofner, Piero V Valli, Arne Kröger, Irina Bergamin, Patrizia Künzler, Adriana Baserga, Dominique Braun, Burkhardt Seifert, Anja Moncsek, Jan Fehr, David Semela, Lorenzo Magenta, Beat Müllhaupt, Benedetta Terziroli Beretta-Piccoli, Joachim C Mertens
BACKGROUND: Novel direct antiviral agents (DAA) targeting hepatitis C virus (HCV) have revolutionized the treatment of chronic hepatitis C infection (CHC). Rates of sustained virological response (SVR) to treatment have drastically improved since introduction of DAA. Transient Elastography (TE) is an ultrasound based, non-invasive technique to assess liver stiffness (LS). We examined the changes in TE values and fibrosis scores FIB-4 and APRI after DAA treatment of CHC. METHODS: 549 patients who received a DAA based treatment for CHC were screened and 392 were included...
September 28, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
25413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"